Genetic engineering technologies allow for the creation of custom-made cells that can have transformative effects on human health. This is best exemplified by chimeric antigen receptor (CAR ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...

Beyond the Point: Learning From Outcomes After Inpatient Immune Checkpoint Inhibitor Therapy Chimeric antigen receptor T-cell (CAR-T) therapies are standard of care for the treatment of several ...

A recently developed cancer treatment called chimeric antigen receptor T-cell therapy (CAR T-cell therapy, for short) offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved ...

This report describes a usually mild syndrome, dubbed LICATS, affecting about three-quarters of CAR T-cell recipients.

Adoptive T cell therapy using Chimeric Antigen Receptor T cells (CAR T) has made significant advances in the treatment of hematologic malignancies and solid tumors. However, a key challenge remains ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

In recent years, CAR-T cell immunotherapy (using chimeric antigen receptors) has revolutionized the fight against cancer. In combination with other tools (chemotherapy, radiotherapy), this new ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of ...